Lördag 20 December | 02:40:57 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Curasight comments on first patient dosing with uTREAT
2025-12-19 17:18:00

Curasight has reached a decisive milestone in its transition toward becoming a clinical-stage therapeutic company. The company has announced the successful dosing of the first patient in the phase I trial of uTREAT for glioblastoma. With no safety issues reported, the study is now officially underway, marking the first time the company’s therapeutic platform is being tested in humans. BioStock reached out to CEO Ulrich Krasilnikoff to discuss the significance of the news.

Read the full interview at biostock.se:

Curasight comments on dosing of first patient with uTREAT
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden